Prelude Therapeutics Inc Quarterly Operating Income (Loss) in USD from Q3 2019 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Prelude Therapeutics Inc quarterly/annual Operating Income (Loss) history and growth rate from Q3 2019 to Q3 2024.
Prelude Therapeutics Inc Operating Income (Loss) for the quarter ending September 30, 2024 was -$34.4M, a 2.97% decline year-over-year.
Prelude Therapeutics Inc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$143M, a 11.7% decline year-over-year.
Prelude Therapeutics Inc annual Operating Income (Loss) for 2023 was -$132M, a 7.07% decline from 2022.
Prelude Therapeutics Inc annual Operating Income (Loss) for 2022 was -$124M, a 8.62% decline from 2021.
Prelude Therapeutics Inc annual Operating Income (Loss) for 2021 was -$114M, a 93.5% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$143M	-$34.4M	-$991K	-2.97%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-06
Q2 2024	-$142M	-$37.2M	-$4.77M	-14.7%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-12
Q1 2024	-$138M	-$34.3M	-$5.23M	-18%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-07
Q4 2023	-$132M	-$37.4M	-$3.99M	-12%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-15
Q3 2023	-$128M	-$33.4M	-$2.98M	-9.8%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-06
Q2 2023	-$125M	-$32.4M	-$2.94M	-9.97%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-12
Q1 2023	-$122M	-$29.1M	+$1.17M	+3.87%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-07
Q4 2022	-$124M	-$33.4M	-$375K	-1.14%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-15
Q3 2022	-$123M	-$30.4M	+$430K	+1.39%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-01
Q2 2022	-$124M	-$29.5M	-$1.54M	-5.51%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-03
Q1 2022	-$122M	-$30.3M	-$8.32M	-37.9%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-08
Q4 2021	-$114M	-$33M	-$13.6M	-69.8%	Oct 1, 2021	Dec 31, 2021	10-K	2023-03-15
Q3 2021	-$100M	-$30.8M	-$12.7M	-70%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-14
Q2 2021	-$87.5M	-$27.9M	-$16.5M	-144%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	-$71M	-$22M	-$12.2M	-126%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-10
Q4 2020	-$58.8M	-$19.4M			Oct 1, 2020	Dec 31, 2020	10-K	2022-03-17
Q3 2020		-$18.1M	-$11.3M	-164%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-12
Q2 2020		-$11.4M			Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-12
Q1 2020		-$9.74M			Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-11
Q3 2019		-$6.88M			Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-10

* An asterisk sign (*) next to the value indicates that the value is likely invalid.